Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach.

Khatoon N, Pandey RK, Prajapati VK. · 2017

Read Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach. by Khatoon N, Pandey RK, Prajapati VK. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5557753.txt.

Introduction

Khatoon, Pandey, and Prajapati present a vaccine design study in Scientific Reports. Their target is visceral leishmaniasis, a fatal parasitic disease found in 70 countries. Drug resistance and weak health systems make a vaccine urgent. No licensed vaccine exists yet.

The team used computer-based immunology tools to build a candidate vaccine. They chose protein pieces from Leishmania secretory proteins. The pieces were picked to trigger both B cells and T cells. That mix should build long-term immune memory. They then modeled the construct and tested its fit with a receptor in simulation. Safety traits were predicted as well. The authors note lab testing is still required. Readers get a full in-silico design pipeline.

Catalog record

CREATORKhatoon N, Pandey RK, Prajapati VK.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE50 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5557753

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Exploring Leishmania secretory proteins to design B and T cell multi-epitope subunit vaccine using immunoinformatics approach By Nazia Khatoon, Rajan Kumar Pandey, Vijay Kumar Prajapati Published in: Scientific Reports DOI: 10.1038/s41598-017-08842-w ABSTRACT Abstract Visceral leishmaniasis (VL) is a fatal form of leishmaniasis which affects 70 countries, worldwide. Increasing drug resistance, HIV co-infection, and poor health system require operative vaccination strategy to control the VL transmission dynamics. Therefore, a holistic approach is needed to generate T and B memory cells to mediate long-term immunity against VL infection. Consequently, immunoinformatics approach was applied to design Leishmania secretory protein based multi-epitope subunit vaccine construct consisting of B and T cell epitopes. Further, the physiochemical characterization was performed to check the aliphatic index, theoretical PI, molecular weight, and thermostable nature of vaccine construct. The allergenicity and antigenicity were also predicted to ensure the safety and immunogenic behavior of final vaccine construct. Moreover, homology modeling, followed by molecular docking and molecular dynamics simulation study was also performed to evaluate the binding affinity and stability of receptor (TLR-4) and ligand (vaccine protein) complex. This study warrants the experimental validation to ensure the immunogenicity and safety profile of presented vaccine construct which may be further helpful to control VL infection. INTRODUCTION Leishmania parasites are responsible for a family of diseases, known as leishmaniasis with different clinical manifestation ranging from cutaneous lesions to fatal systemic disease1. Visceral leishmaniasis (VL) has been classified as one of the most neglected diseases; the estimated disease burden places it second in mortality and fourth in morbidity among the tropical infectious diseases2, 3. Currently available antileishmanial treatments are based on chemotherapy but the accessible drugs are toxic, have serious side effects and are related to numerous failures along with increased incidence of drug resistance4, 5. There are only a few compounds such as sitamaquine and imidazole that are in pipeline, which still requires pharmaceutical investigations and clinical trials at large level. Foot to mouth situation of people living in the endemic zones is limiting the reach of vector control measures6, 7. Development of new vaccines can now take advantage of a much greater knowledge of the complexities of the immune system and of the development of powerful molecular techniques that allow targeted changes to be made in pathogenic organisms and in experimental host8. Vaccine development has become much more sophisticated where immunologists working closely with molecular biologists and chemical engineers to design and produce highly purified vaccines that are safe and effective9. The development of a successful vaccine to prevent VL disease condition has been a goal for almost a century, but currently no such vaccine exists10. Immunoprophylaxis and vaccination need to develop for the control of this disease11. Secretory proteins of pathogens are antigenic in nature and are capable of inducing a significant immunogenic response into the host. Therefore, many vaccine candidates have been derived from secretory proteins of pathogen12. B cell epitopes are part of proteins which prime the antigenicity and recognized by the human antibodies. Identification of B and T cell epitopes are useful for the development of a novel vaccine13. During the VL infection, T cells become an effector cell and kill an infected cell after the activation of antigen-presenting cells14. The peptide fragments of the pathogen and the MHC molecules bind together and appear on the cell surface of infected host cells. A diverse range of peptides is bound to each allelic form of MHC protein15. The MHC molecule has the ability to bind with peptides tightly as the pathogens try to mutate the epitope of the MHC molecule. Hence, MHC molecule exhibits high binding affinity with a variety of peptides16. Vaccination, or immunization, work by stimulating the immune system, the natural disease-fighting system of the body17. With the discoveries of newer technologies, the conventional empirical approaches to vaccine development have given a way to design rational vaccines18. Improved understanding of pathogen variability as well as the diversity of the human immune system, plus technological advances in genetic and molecular biology provide better insights in the host–pathogen interaction and new avenues for vaccine development19. In past decade, important advances have been made in the field of the basic immunology. These include the interpretation of the MHC restriction, which concluded in the elucidation of the T cell receptor and the three-dimensional structure of an MHC molecule; the identification of intercellular signaling molecules (cytokines) and the nature of the antigen presentation. However, this application just begins to control the infectious disease. MHC molecules are critical in transplantation, autoimmunity, infections, and tumor immunotherapy. The combined understanding of antigen presentation by MHC molecules allows exploitation to improve the responses of the cellular arm of the immune system towards vaccinations and immunotherapies20. Vaccination has been considered as a safest and efficacious way to control the vector-borne parasitic diseases. In the beginning days, development of immunization against leishmaniasis infection involves the inoculation of live or autoclaved Leishmania parasites. But because of safety concern, it is not in practice now for the human use. Several types of the antigens collected from Leishmania donovani were used as a vaccine candidate to improve the humoral as well as cell-mediated immune response. These efforts were rejected because of antigenic variability and gene polymorphism in the clinical isolates circulating in the endemic region. Different recombinant proteins which include KMP-11, A2, CPB, and gp63 have proven immunogenic response in the animal model but these were not able to reach up to clinical trials. Leish-111F/MPL-SE is one of the multi-subunit recombinant vaccines which have shown a safe response in South America against cutaneous & mucocutaneous leishmaniasis and cured visceral leishmaniasis patients in India21. But still, it is far from the VL clinical trial22. Immunoinformatics approach for the identification of novel vaccine is a recently developed method which can predict a thermodynamically stable and multi-epitope subunit vaccine in a very less time. Hence, here we propose to design a multi-epitope subunit model vaccine composed of immunogenic epitopes which may have the ability to activate host humoral and cell-mediated immune system. RESULTS Collection of Leishmania donovani protein sequences for vaccine construction The amino acid sequence of five secretory proteins of L. donovani was retrieved from Gene Bank Database in FASTA format and used for designing a potential multi-epitope vaccine against VL infection. The amino acid sequences of L. donovani secretory proteins (LdBPK_190160,hypothetical protein conserved ; LdBPK_211410, Surface antigen-like protein; LdBPK_310120, FG-GAP repeat protein; LdBPK_220130, Translocon-associated protein and LdBPK_310860, Secretory lipase) were selected based on their respective D-score which was obtained using SignalP server. Further, 50S ribosomal protein L7/L12 (Locus RL7_MYCTU) P9WHE3 was retrieved from the UniProt database to be used as an adjuvant. Cytotoxic T Lymphocytes (CTL) and Helper T Lymphocytes (HTL) epitopes prediction A total of 39 CTL epitopes (9-mer) were predicted by using NetCTL 1.2 server, among them only 8 epitopes with high ranked binding affinity score were chosen as final CTL epitopes for the input of L. donovani secretory protein sequences (Supplementary Table-1). Similarly, the HTL epitopes were identified using IEDB MHC-II prediction module based on the higher binding affinity with MHC- II. The mouse alleles used for the prediction were H2-1Ad, H2-1Ed, and H2-1Ab. HTL epitopes were selected from LdBPK_190160 situated at position 235–249, 221–235 and 761–775; LdBPK_211410 at

Read the complete text